The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

Launched by RUIJIN HOSPITAL · Apr 21, 2021

Keywords

ClinConnect Summary

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA) is a clinical trial aimed at better understanding a kidney condition known as IgA nephropathy (IgAN). This study is setting up a group of experts to collect and analyze data from patients with IgAN. By creating a standardized database, researchers hope to gather important information about how this condition is diagnosed and treated across different hospitals. This will help improve future research and potentially lead to better treatments for IgAN.

Anyone with a confirmed diagnosis of IgA nephropathy can participate, regardless of their age or gender. To join, participants must voluntarily agree to take part in the study and have had a kidney biopsy that confirms their condition. However, those whose IgAN is caused by other diseases or who haven’t had a biopsy confirming the diagnosis will not be included. If you join, you can expect to contribute to an important effort that could help many others with IgA nephropathy by improving our understanding of this disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. No age limit, no gender limit;
• • 2. Kidney biopsy confirmed primary IgA nephropathy;
• • 3. Sign the informed consent form voluntarily
• Exclusion Criteria:
• • 1. IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura;
• • 2. IgAN is clinically diagnosed but not confirmed by pathology;
• • 3. The patient refuses to participate;
• • 4. Patients judged by other investigators to be unsuitable for inclusion in the study.